Chinese Academy of Sciences

Shanghai Haihe Pharmaceutical Co., Ltd.

Jinan University

Haihe Biopharma Co., Ltd.

Yinchun Ji

Meiyu Geng

Xia Peng

Jing Ai

Jian Ding

Jingkang Shen

Bing Xiong

Danqi Chen

Jian Li

Zhang Zhang

Xin Wang

Qi Rong Wang

Jia Tao Li

Hualiang Jiang

Kaixian Chen

Ke Ding

Tao Meng

Zhengchao Tu

Lanping Ma

Li Tan

Xiaoyun Lu

Xiaomei Ren

Yu Zhou

Hong Liu

Wenhu Duan

Yi Zang

Qian Tan

Yang Dai

Feifei Fang

Shingpan Chan

Jing Al

Yuchi Ma

Yuelei Chen

Hefeng Zhang

Ying Dong

Qi Wang

Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.

Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof

A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof are provided. Specifically, provided herein are a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.

Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof

The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof. 

Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumors associated with abnormal protein tyrosine kinase. 

Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof

Growing community of inventors

Shanghai, China

Yinchun Ji